Predictors of mortality following treatment of intracranial hemangiopericytoma

Martin J. Rutkowski, Michael E. Sughrue, Ari J. Kane, Derick Aranda, Steven A. Mills, Igor J. Barani, Andrew T. Parsa

Research output: Contribution to journalArticle

Abstract

Object. Intracranial hemangiopericytoma (HPC) is a rare and malignant extraaxial tumor with a high proclivity toward recurrence and metastasis. Given this lesion's rarity, little information exists on prognostic factors influencing mortality rates following treatment with surgery or radiation or both. A systematic review of the published literature was performed to ascertain predictors of death following treatment for intracranial HPC. Methods. The authors identified 563 patients with intracranial HPC in the published literature, 277 of whom had information on the duration of follow-up. Statistical analysis of survival was performed using Kaplan-Meier and Cox regression analysis. Results. Hemangiopericytoma was diagnosed in 246 males and 204 females, ranging in age from 1 month to 80 years. Among patients treated for HPC, overall median survival was 13 years, with 1-, 5-, 10-, and 20-year survival rates of 95%, 82%, 60%, and 23%, respectively. Gross-total resection alone (105 patients) was associated with superior survival rates overall, with a median survival of 13 years, whereas subtotal resection alone (23 patients) resulted in a median survival of 9.75 years. Subtotal resection plus adjuvant radiotherapy led to a median survival of 6 years. Gross-total resection was associated with a superior survival benefit to patients regardless of the addition or absence of radiation, and patients receiving > 50 Gy of radiation had worse survival outcomes (median survival 4 vs 18.6 years, p < 0.01, log-rank test). Patients with tumors of the posterior fossa had a median survival of 10.75 versus 15.6 years for those with non-posterior fossa tumors (p < 0.05, log-rank test). Conclusions. Treatment with gross-total resection provides the greatest survival advantage and should be pursued aggressively as an initial therapy. The addition of postoperative adjuvant radiation does not seem to confer a survival benefit.

Original languageEnglish (US)
Pages (from-to)333-339
Number of pages7
JournalJournal of neurosurgery
Volume113
Issue number2
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Hemangiopericytoma
Survival
Mortality
Therapeutics
Radiation
Survival Rate
Infratentorial Neoplasms
Radiation Dosage
Adjuvant Radiotherapy
Survival Analysis
Neoplasms
Regression Analysis
Neoplasm Metastasis

Keywords

  • Hemangiopericytoma
  • Intracranial
  • Mortality
  • Predictor
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Aranda, D., Mills, S. A., Barani, I. J., & Parsa, A. T. (2010). Predictors of mortality following treatment of intracranial hemangiopericytoma. Journal of neurosurgery, 113(2), 333-339. https://doi.org/10.3171/2010.3.JNS091882

Predictors of mortality following treatment of intracranial hemangiopericytoma. / Rutkowski, Martin J.; Sughrue, Michael E.; Kane, Ari J.; Aranda, Derick; Mills, Steven A.; Barani, Igor J.; Parsa, Andrew T.

In: Journal of neurosurgery, Vol. 113, No. 2, 01.08.2010, p. 333-339.

Research output: Contribution to journalArticle

Rutkowski, MJ, Sughrue, ME, Kane, AJ, Aranda, D, Mills, SA, Barani, IJ & Parsa, AT 2010, 'Predictors of mortality following treatment of intracranial hemangiopericytoma', Journal of neurosurgery, vol. 113, no. 2, pp. 333-339. https://doi.org/10.3171/2010.3.JNS091882
Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, Mills SA, Barani IJ et al. Predictors of mortality following treatment of intracranial hemangiopericytoma. Journal of neurosurgery. 2010 Aug 1;113(2):333-339. https://doi.org/10.3171/2010.3.JNS091882
Rutkowski, Martin J. ; Sughrue, Michael E. ; Kane, Ari J. ; Aranda, Derick ; Mills, Steven A. ; Barani, Igor J. ; Parsa, Andrew T. / Predictors of mortality following treatment of intracranial hemangiopericytoma. In: Journal of neurosurgery. 2010 ; Vol. 113, No. 2. pp. 333-339.
@article{2e6bd93222a14fa09e9153b00f23d454,
title = "Predictors of mortality following treatment of intracranial hemangiopericytoma",
abstract = "Object. Intracranial hemangiopericytoma (HPC) is a rare and malignant extraaxial tumor with a high proclivity toward recurrence and metastasis. Given this lesion's rarity, little information exists on prognostic factors influencing mortality rates following treatment with surgery or radiation or both. A systematic review of the published literature was performed to ascertain predictors of death following treatment for intracranial HPC. Methods. The authors identified 563 patients with intracranial HPC in the published literature, 277 of whom had information on the duration of follow-up. Statistical analysis of survival was performed using Kaplan-Meier and Cox regression analysis. Results. Hemangiopericytoma was diagnosed in 246 males and 204 females, ranging in age from 1 month to 80 years. Among patients treated for HPC, overall median survival was 13 years, with 1-, 5-, 10-, and 20-year survival rates of 95{\%}, 82{\%}, 60{\%}, and 23{\%}, respectively. Gross-total resection alone (105 patients) was associated with superior survival rates overall, with a median survival of 13 years, whereas subtotal resection alone (23 patients) resulted in a median survival of 9.75 years. Subtotal resection plus adjuvant radiotherapy led to a median survival of 6 years. Gross-total resection was associated with a superior survival benefit to patients regardless of the addition or absence of radiation, and patients receiving > 50 Gy of radiation had worse survival outcomes (median survival 4 vs 18.6 years, p < 0.01, log-rank test). Patients with tumors of the posterior fossa had a median survival of 10.75 versus 15.6 years for those with non-posterior fossa tumors (p < 0.05, log-rank test). Conclusions. Treatment with gross-total resection provides the greatest survival advantage and should be pursued aggressively as an initial therapy. The addition of postoperative adjuvant radiation does not seem to confer a survival benefit.",
keywords = "Hemangiopericytoma, Intracranial, Mortality, Predictor, Survival",
author = "Rutkowski, {Martin J.} and Sughrue, {Michael E.} and Kane, {Ari J.} and Derick Aranda and Mills, {Steven A.} and Barani, {Igor J.} and Parsa, {Andrew T.}",
year = "2010",
month = "8",
day = "1",
doi = "10.3171/2010.3.JNS091882",
language = "English (US)",
volume = "113",
pages = "333--339",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - Predictors of mortality following treatment of intracranial hemangiopericytoma

AU - Rutkowski, Martin J.

AU - Sughrue, Michael E.

AU - Kane, Ari J.

AU - Aranda, Derick

AU - Mills, Steven A.

AU - Barani, Igor J.

AU - Parsa, Andrew T.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Object. Intracranial hemangiopericytoma (HPC) is a rare and malignant extraaxial tumor with a high proclivity toward recurrence and metastasis. Given this lesion's rarity, little information exists on prognostic factors influencing mortality rates following treatment with surgery or radiation or both. A systematic review of the published literature was performed to ascertain predictors of death following treatment for intracranial HPC. Methods. The authors identified 563 patients with intracranial HPC in the published literature, 277 of whom had information on the duration of follow-up. Statistical analysis of survival was performed using Kaplan-Meier and Cox regression analysis. Results. Hemangiopericytoma was diagnosed in 246 males and 204 females, ranging in age from 1 month to 80 years. Among patients treated for HPC, overall median survival was 13 years, with 1-, 5-, 10-, and 20-year survival rates of 95%, 82%, 60%, and 23%, respectively. Gross-total resection alone (105 patients) was associated with superior survival rates overall, with a median survival of 13 years, whereas subtotal resection alone (23 patients) resulted in a median survival of 9.75 years. Subtotal resection plus adjuvant radiotherapy led to a median survival of 6 years. Gross-total resection was associated with a superior survival benefit to patients regardless of the addition or absence of radiation, and patients receiving > 50 Gy of radiation had worse survival outcomes (median survival 4 vs 18.6 years, p < 0.01, log-rank test). Patients with tumors of the posterior fossa had a median survival of 10.75 versus 15.6 years for those with non-posterior fossa tumors (p < 0.05, log-rank test). Conclusions. Treatment with gross-total resection provides the greatest survival advantage and should be pursued aggressively as an initial therapy. The addition of postoperative adjuvant radiation does not seem to confer a survival benefit.

AB - Object. Intracranial hemangiopericytoma (HPC) is a rare and malignant extraaxial tumor with a high proclivity toward recurrence and metastasis. Given this lesion's rarity, little information exists on prognostic factors influencing mortality rates following treatment with surgery or radiation or both. A systematic review of the published literature was performed to ascertain predictors of death following treatment for intracranial HPC. Methods. The authors identified 563 patients with intracranial HPC in the published literature, 277 of whom had information on the duration of follow-up. Statistical analysis of survival was performed using Kaplan-Meier and Cox regression analysis. Results. Hemangiopericytoma was diagnosed in 246 males and 204 females, ranging in age from 1 month to 80 years. Among patients treated for HPC, overall median survival was 13 years, with 1-, 5-, 10-, and 20-year survival rates of 95%, 82%, 60%, and 23%, respectively. Gross-total resection alone (105 patients) was associated with superior survival rates overall, with a median survival of 13 years, whereas subtotal resection alone (23 patients) resulted in a median survival of 9.75 years. Subtotal resection plus adjuvant radiotherapy led to a median survival of 6 years. Gross-total resection was associated with a superior survival benefit to patients regardless of the addition or absence of radiation, and patients receiving > 50 Gy of radiation had worse survival outcomes (median survival 4 vs 18.6 years, p < 0.01, log-rank test). Patients with tumors of the posterior fossa had a median survival of 10.75 versus 15.6 years for those with non-posterior fossa tumors (p < 0.05, log-rank test). Conclusions. Treatment with gross-total resection provides the greatest survival advantage and should be pursued aggressively as an initial therapy. The addition of postoperative adjuvant radiation does not seem to confer a survival benefit.

KW - Hemangiopericytoma

KW - Intracranial

KW - Mortality

KW - Predictor

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77955625844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955625844&partnerID=8YFLogxK

U2 - 10.3171/2010.3.JNS091882

DO - 10.3171/2010.3.JNS091882

M3 - Article

C2 - 20367074

AN - SCOPUS:77955625844

VL - 113

SP - 333

EP - 339

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -